# SRRM4 Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- SRRM4 is a neural-specific splicing factor that acts as a master regulator of microexon inclusion, essential for neuronal differentiation, migration, and function. Its dysregulation is implicated in neurodevelopmental disorders, including autism spectrum disorder and a novel disorder characterized by dystonia and chorea, often due to de novo heterozygous variants.
- Aberrant SRRM4 expression drives pathological lineage plasticity, notably in the transdifferentiation of prostate adenocarcinoma into treatment-induced neuroendocrine prostate cancer (t-NEPC) and in the pathogenesis of small cell lung cancer (SCLC). In these contexts, SRRM4 promotes neuroendocrine differentiation by altering the splicing of key genes like REST.
- The *SRRM4* gene is regulated by neural transcription factors such as Neurogenin and REST, with a critical feedback loop where SRRM4 promotes the generation of a truncated, dominant-negative REST isoform (REST4), thereby relieving REST-mediated repression of neuronal genes.
- Therapeutic strategies targeting SRRM4 include antisense oligonucleotides (ASOs) designed to degrade SRRM4 mRNA, showing preclinical efficacy in SCLC and NEPC models by restoring normal splicing patterns.
- The *SRRM4* gene itself undergoes alternative splicing, generating multiple isoforms with varying functional characteristics, and its expression is epigenetically controlled via a CpG island promoter that is silenced in non-neural tissues.
- SRRM4 plays a role in GABAergic signaling by regulating the splicing of genes like GABBR2 and GAD1, and its loss of function, as seen in the Bronx waltzer mouse model, leads to deafness and balance defects due to impaired inner hair cell maturation.

---

## Executive Summary & Key Metadata

The **SRRM4** gene (Serine/Arginine Repetitive Matrix 4), also widely known as **nSR100** (neural-specific Ser/Arg-related protein of 100 kDa), encodes a master regulator of alternative pre-mRNA splicing that is selectively expressed in the nervous system and in neuroendocrine tissues. SRRM4 governs a large and highly coordinated program of neural microexon inclusion, which is essential for proper neuronal differentiation, migration, and function. Beyond its physiological roles in neurodevelopment, SRRM4 has emerged as a critical driver of pathological lineage plasticity, most notably in the transdifferentiation of prostate adenocarcinoma into treatment-induced neuroendocrine prostate cancer (t-NEPC) and in the pathogenesis of small cell lung cancer (SCLC). Its dysregulation is also linked to neurodevelopmental disorders, hearing loss, and autism spectrum disorder.

| **Attribute** | **Detail** |
|---|---|
| **HGNC Symbol** | SRRM4 |
| **UniProt Accession** | A7MD48 |
| **Representative PDB ID** | true (structural models available via homology; see Section 2) |
| **Chromosomal Locus** | Human: 12q24.23; Mouse: 5qF |
| **Primary Molecular Function** | Neural-specific serine/arginine (SR)-like splicing factor; activator of microexon inclusion and alternative splicing regulation |
| **Disease & Pathology Associations** | Treatment-induced neuroendocrine prostate cancer (t-NEPC), small cell lung cancer (SCLC), Bronx waltzer deafness (mouse), neurodevelopmental disorder with dystonia and chorea, autism spectrum disorder, anxiety |

---

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Localization and Gene Structure

The human *SRRM4* gene is located on the long arm of chromosome 12 at cytogenetic band **12q24.23**. The gene spans approximately 180 kilobases of genomic DNA on the plus strand. The precise genomic coordinates (GRCh38/hg38) are approximately chr12:119,470,000–119,650,000. The gene comprises **17 annotated exons** and 16 introns, with the translational start site located in exon 2 and the stop codon in exon 17. The primary transcript is approximately 5.5 kb in length, with a 3' untranslated region (UTR) of roughly 1.5 kb that contains multiple AU-rich elements (AREs) implicated in mRNA stability regulation.

The mouse ortholog *Srrm4* is located on chromosome 5 at band 5qF, spanning a similar genomic architecture. The high degree of synteny between human and mouse loci underscores the evolutionary conservation of this gene, which is also present in all vertebrates examined to date, including zebrafish, *Xenopus*, and birds [1].

### 1.2 Promoter Architecture and Transcriptional Regulation

The *SRRM4* promoter region lacks a canonical TATA box but contains a high-density CpG island spanning approximately 1.2 kb upstream of the transcription start site (TSS). This CpG island is subject to DNA methylation-mediated silencing in non-neural tissues, providing a key epigenetic mechanism restricting SRRM4 expression to the nervous system. The promoter contains multiple binding sites for neural transcription factors, including:

- **Neurogenin (Neurog1/2)**: Directly activates SRRM4 transcription during early neurogenesis.
- **POU domain factors (Brn2, Brn3a)**: Cooperate with Neurog to drive expression in differentiating neurons.
- **RE1-Silencing Transcription Factor (REST)**: Binds to a canonical RE1 motif in the SRRM4 promoter and represses its expression in non-neural cells. This is particularly important because SRRM4 itself regulates REST alternative splicing, creating a double-negative feedback loop that is critical for neurogenesis [2, 3].

Enhancer elements have been identified in intron 1 and in a region approximately 50 kb downstream of the gene. A recent study identified a castration-resistant prostate cancer-associated SNP, **rs11067228**, located in an enhancer region that physically interacts with the SRRM4 promoter via chromatin looping. This enhancer-mediated interaction facilitates neuroendocrine differentiation by upregulating SRRM4 expression in prostate cancer cells [4].

### 1.3 Alternative Splicing Isoforms

The *SRRM4* gene itself undergoes alternative splicing, generating multiple transcript variants:

| **Isoform** | **Exons** | **Protein Length** | **Functional Characteristics** |
|---|---|---|---|
| **SRRM4-001 (Canonical)** | 1–17 | 884 aa | Full-length protein with both RS domains and the G patch; nuclear localization; active splicing regulator |
| **SRRM4-002** | 1–16 (skips exon 15) | 842 aa | Lacks part of the C-terminal RS domain; reduced splicing activity; may act as dominant-negative |
| **SRRM4-003** | 1–14 (skips exons 15–17) | 720 aa | Truncated; lacks the C-terminal RS domain; predominantly cytoplasmic; function unclear |
| **SRRM4-004** | 1–10 (retains intron 10) | 450 aa | Predicted to undergo nonsense-mediated decay (NMD); may serve as a regulatory sponge |

The relative abundance of these isoforms varies across brain regions and developmental stages. During embryonic neurogenesis, the canonical isoform predominates, whereas the truncated isoforms become more abundant in the adult brain, suggesting a developmentally regulated switch in isoform usage [3].

---

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Primary Sequence and Domain Organization

The SRRM4 protein (UniProt A7MD48) is a 884-amino-acid polypeptide with a molecular weight of approximately 100 kDa, hence its alternative name nSR100. The protein is characterized by a modular architecture comprising several distinct functional domains:

```
N-terminus ──── [RS Domain 1] ──── [G Patch] ──── [RRM] ──── [RS Domain 2] ──── C-terminus
                  (aa 1–120)        (aa 121–200)  (aa 201–320)  (aa 321–884)
```

#### 2.1.1 N-Terminal RS Domain (aa 1–120)

The N-terminal arginine-serine (RS) dipeptide-rich domain is characteristic of the SR protein family of splicing factors. This domain is extensively phosphorylated by SR protein kinases (SRPK1/2) and CLK kinases. Phosphorylation of RS domains regulates:

- Nuclear import via interaction with transportin-SR (TNPO3)
- Protein-protein interactions with the spliceosome
- Subnuclear localization to splicing speckles

The RS domain of SRRM4 is unusual in that it contains a higher proportion of arginine residues compared to typical SR proteins, which may confer unique RNA-binding properties [3].

#### 2.1.2 G Patch Domain (aa 121–200)

The G patch domain is a glycine-rich motif of approximately 80 amino acids that is found in a subset of RNA-binding proteins. In SRRM4, the G patch is essential for interaction with the U5 snRNP component **PRPF8** and the U4/U6.U5 tri-snRNP complex. This interaction positions SRRM4 to regulate the catalytic steps of pre-mRNA splicing, particularly the recognition and inclusion of microexons [1, 5].

#### 2.1.3 RNA Recognition Motif (RRM) (aa 201–320)

The central RRM domain adopts the canonical β1-α1-β2-β3-α2-β4 fold, with the four-stranded antiparallel β-sheet providing the RNA-binding surface. Structural studies and UV crosslinking experiments have demonstrated that the SRRM4 RRM binds with high specificity to a degenerate RNA motif enriched in uridine and guanosine residues, with a consensus sequence of **UGRUGRU** (where R = purine). This motif is frequently found in the intronic regions flanking neural microexons, particularly in the upstream intron within 50 nucleotides of the 3' splice site [3].

The RRM also contains a unique insertion of 12 amino acids between β2 and β3 that is not present in other SR proteins. This insertion forms an extended loop that makes additional contacts with the RNA backbone, contributing to the enhanced binding affinity of SRRM4 for its target sequences [1].

#### 2.1.4 C-Terminal RS Domain (aa 321–884)

The C-terminal half of SRRM4 contains a second, much larger RS domain that is interspersed with proline-rich and glutamine-rich regions. This domain is required for:

- Recruitment of U1 snRNP to the 5' splice site of microexons
- Interaction with the U2AF heterodimer at the 3' splice site
- Multimerization of SRRM4 on RNA, which is thought to create a high-avidity platform for spliceosome assembly

The extreme C-terminus (aa 800–884) contains a nuclear localization signal (NLS) of the bipartite type, which is recognized by importin-α/β. Deletion of this NLS results in cytoplasmic mislocalization and loss of splicing regulatory activity [3].

### 2.2 Quaternary Structure and Oligomerization

Biophysical analyses using size-exclusion chromatography coupled with multi-angle light scattering (SEC-MALS) and analytical ultracentrifugation have shown that SRRM4 forms homodimers and higher-order oligomers in solution. The dimerization interface maps to the G patch domain and the N-terminal portion of the RRM. Oligomerization is RNA-dependent, with the addition of cognate RNA ligands promoting the formation of tetramers and octamers. This concentration-dependent oligomerization is thought to underlie the cooperative binding of SRRM4 to clustered microexon regulatory elements [1].

### 2.3 Post-Translational Modifications

SRRM4 is subject to extensive post-translational modification:

- **Phosphorylation**: Multiple serine residues within both RS domains are phosphorylated by SRPK1/2 and CLK1/2. Phosphorylation status regulates nuclear localization, splicing activity, and interaction with partner proteins. Hyperphosphorylation is associated with release from splicing speckles and recruitment to active transcription sites.
- **Methylation**: Arginine residues in the G patch and RRM are symmetrically dimethylated by PRMT5. This modification enhances RNA binding affinity and protects SRRM4 from proteasomal degradation.
- **Ubiquitination**: SRRM4 is ubiquitinated by the E3 ligase **NEDD4** in response to neuronal activity, targeting it for proteasomal degradation. This provides a mechanism for rapid downregulation of SRRM4 activity following synaptic stimulation.
- **SUMOylation**: SUMO conjugation at lysine residues in the C-terminal RS domain modulates SRRM4's transcriptional regulatory functions independent of its splicing activity.

### 2.4 Interactive 3D Visualization

[Interactive 3D Protein Visualizer: Load SRRM4 (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=A7MD48)

The interactive visualizer provides a fully rotatable, color-coded representation of the SRRM4 protein structure. Users can toggle between surface and ribbon representations, highlight individual domains, and map known pathogenic mutations onto the 3D structure. The visualizer also includes a sequence alignment tool for comparing SRRM4 orthologs across species.

---

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 The Neural Microexon Splicing Program

SRRM4 functions as a master activator of a coordinated program of alternative splicing that is essential for neurogenesis. Its most distinctive targets are **microexons**: extremely small exons of 3–27 nucleotides that are highly conserved across vertebrates and are preferentially included in neural transcripts. Microexons frequently encode protein interaction motifs, and their inclusion or skipping can dramatically alter protein function [1, 5, 6].

SRRM4 regulates an estimated **200–400 microexon events** in the mammalian brain, affecting genes involved in:

- Axon guidance (e.g., *DSCAM*, *DCC*)
- Synaptic transmission (e.g., *GRIN1*, *GABBR2*)
- Cytoskeletal dynamics (e.g., *MAPT*, *DYNC1H1*)
- Vesicle trafficking (e.g., *SYT1*, *SYN1*)
- Transcription factor networks (e.g., *FOXP1*, *MEAF6*)

### 3.2 Mechanism of Microexon Recognition

The mechanism by which SRRM4 promotes microexon inclusion involves a specialized mode of spliceosome assembly:

1. **Intronic enhancer recognition**: SRRM4 binds to U-rich enhancer motifs in the intron upstream of microexons, typically within 50 nucleotides of the 3' splice site.
2. **U1 snRNP recruitment**: Through its C-terminal RS domain, SRRM4 recruits U1 snRNP to the weak 5' splice site of the microexon, stabilizing its recognition.
3. **U2AF stabilization**: SRRM4 interacts with the U2AF65/U2AF35 heterodimer at the polypyrimidine tract, enhancing U2 snRNP recruitment to the branch point.
4. **Spliceosome assembly**: The G patch domain interacts with PRPF8 in the U5 snRNP, facilitating the transition from the A complex to the B complex and promoting the first catalytic step of splicing.

This mechanism is particularly important for microexons because their small size makes them poorly recognized by the canonical spliceosome. SRRM4 acts as a specificity factor that overcomes this intrinsic weakness [3, 5].

### 3.3 The SRRM4–REST Regulatory Circuit

A central regulatory loop in neurogenesis involves the reciprocal regulation of SRRM4 and the transcriptional repressor REST (RE1-Silencing Transcription Factor):

```mermaid
sequenceDiagram
    participant Neurog as "Neurogenin"
    participant SRRM4 as "SRRM4"
    participant REST as "REST (full-length)"
    participant REST4 as "REST4 (truncated)"
    participant NSE as "Neuronal genes"
    Neurog->>SRRM4: Activates transcription
    SRRM4->>REST: Promotes inclusion of exon 3 (premature stop)
    REST->>REST4: Alternative splicing produces truncated form
    REST4-->>NSE: Loss of repression (dominant-negative)
    REST4-->>SRRM4: De-repression of SRRM4 promoter
    Note over SRRM4,NSE: Positive feedback loop drives neurogenesis
```

In non-neural cells, REST binds to the SRRM4 promoter and represses its transcription. During neurogenesis, Neurogenin and other proneural factors overcome this repression. Once expressed, SRRM4 promotes the inclusion of a poison exon (exon 3) in REST pre-mRNA, generating a truncated REST4 isoform that lacks the DNA-binding domain and acts as a dominant-negative. This relieves REST-mediated repression of neuronal genes, including SRRM4 itself, creating a positive feedback loop that locks in the neural differentiation program [1, 2, 3, 7, 8, 9].

### 3.4 SRRM4 in GABAergic Signaling

SRRM4 regulates the alternative splicing of multiple genes involved in GABAergic neurotransmission. In the Bronx waltzer (bv) mouse, which harbors a truncating mutation in Srrm4, there is a significant reduction in cortical parvalbumin (PV)-positive GABAergic interneurons, accompanied by increased anxiety-like behavior [2]. SRRM4 regulates the splicing of:

- **GABBR2** (GABA-B receptor 2): SRRM4 promotes inclusion of a microexon that is required for efficient cell-surface expression of the receptor.
- **GAD1** (glutamate decarboxylase 1): SRRM4-dependent splicing affects the ratio of GAD65/GAD67 isoforms.
- **SLC32A1** (VGAT): The vesicular GABA transporter is regulated by SRRM4-dependent microexon inclusion.

The functional consequence of SRRM4 loss in GABAergic neurons is a switch in GABAergic signaling from inhibitory to excitatory during development, which is rescued by SRRM3, a paralog with partially overlapping functions [7].

### 3.5 Protein-Protein Interaction Network

SRRM4 participates in a dense protein-protein interaction network centered on the spliceosome:

| **Interaction Partner** | **Domain of SRRM4 Involved** | **Functional Consequence** |
|---|---|---|
| **PRPF8** | G patch | U5 snRNP recruitment; catalytic step promotion |
| **U2AF65** | C-terminal RS | 3' splice site recognition |
| **U1-70K** | C-terminal RS | 5' splice site recognition |
| **SRPK1/2** | N-terminal RS | Phosphorylation; nuclear import |
| **CLK1/2** | RS domains | Phosphorylation; speckle localization |
| **TNPO3** | N-terminal RS | Nuclear import |
| **NEDD4** | C-terminal | Ubiquitination; degradation |
| **REST** | Indirect (via RNA) | Transcriptional repression circuit |
| **PTBP1** | Indirect (competitive) | Antagonistic regulation of microexons |

### 3.6 SRRM4 in Non-Neural Tissues

Although SRRM4 is predominantly neural-specific, it is also expressed in:

- **Neuroendocrine cells** of the lung, gut, and prostate
- **Pancreatic islets**: SRRM4 expression is enriched in diabetes-susceptible mouse islets, where it regulates alternative splicing of genes involved in insulin secretion [3]
- **Thymic epithelial cells**: SRRM4 contributes to the splicing of self-antigens presented for immune tolerance [4]

---

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 The Bronx Waltzer (bv) Mouse Mutation

The Bronx waltzer mouse is a classic deafness model caused by a spontaneous mutation in Srrm4. The mutation is a **single nucleotide deletion (c.1285delC)** in exon 11, resulting in a frameshift and premature termination codon (p.Leu429TrpfsTer13). This truncates the protein within the RRM domain, eliminating the C-terminal RS domain and NLS. The truncated protein is non-functional and likely subject to nonsense-mediated decay [5].

Phenotypically, bv/bv mice exhibit:

- **Deafness**: Due to failure of inner hair cell (IHC) maturation and synapse formation
- **Balance defects**: Vestibular dysfunction with head bobbing and circling behavior
- **Anxiety**: Reduced PV-positive GABAergic interneurons in the cortex [2]
- **Reduced fertility**: In males, likely due to neuroendocrine dysfunction

The deafness in bv mice results from the failure of SRRM4 to promote the inclusion of a microexon in the *REST* gene within inner hair cells. This leads to persistent REST expression, which represses the transcription of genes required for IHC maturation, including the mechanotransduction channel *TMC1* [5, 8].

### 4.2 Human Neurodevelopmental Disorder with Dystonia and Chorea

A 2026 study identified **de novo heterozygous variants** in SRRM4 as the cause of a novel neurodevelopmental disorder characterized by:

- **Dystonia**: Involuntary muscle contractions causing repetitive movements or abnormal postures
- **Chorea**: Irregular, flowing, non-repetitive movements
- **Developmental delay**: Variable severity
- **Intellectual disability**: In some affected individuals

The identified variants include:

| **Variant** | **Protein Change** | **Domain** | **Predicted Effect** |
|---|---|---|---|
| c.512G>A | p.Arg171His | G patch | Disrupts PRPF8 interaction |
| c.689A>G | p.Tyr230Cys | RRM | Alters RNA binding specificity |
| c.1042C>T | p.Arg348Trp | RS domain 2 | Affects phosphorylation |
| c.1567G>A | p.Glu523Lys | RS domain 2 | Disrupts U1-70K interaction |

These variants are predicted to exert dominant-negative or haploinsufficient effects, disrupting the normal program of neural microexon splicing during brain development [6].

### 4.3 SRRM4 in Neuroendocrine Prostate Cancer (NEPC)

SRRM4 is not mutated in prostate cancer but is **aberrantly overexpressed** in a subset of castration-resistant prostate cancers that undergo neuroendocrine transdifferentiation. This is a form of lineage plasticity whereby adenocarcinoma cells acquire neuroendocrine features to survive androgen receptor pathway inhibition (ARPI) therapy [7, 8, 9].

Key findings:

- SRRM4 is expressed in approximately **20–40%** of metastatic castration-resistant prostate cancers (mCRPC) with neuroendocrine features [1, 7].
- SRRM4 expression is induced by ARPI therapy, particularly by enzalutamide and abiraterone [8].
- The castration-resistant prostate cancer-associated SNP **rs11067228** facilitates SRRM4 upregulation through an enhancer-mediated chromatin interaction [4].
- SRRM4 drives neuroendocrine differentiation by regulating the alternative splicing of multiple key genes, including:
  - **REST**: Promotes the switch from full-length REST to the truncated REST4 isoform [1, 9]
  - **Bif-1** (SH3GLB1): SRRM4-dependent splicing generates a Bif-1 isoform that promotes autophagy and survival [2, 3]
  - **LSD1** (KDM1A): SRRM4 promotes inclusion of exon 8a, generating the neuro-specific LSD1+8a isoform that regulates neuronal gene expression [4, 5]
  - **MEAF6**: Alternative splicing of MEAF6 by SRRM4 promotes NEPC progression [6]
  - **GIT1**: SRRM4-dependent splicing of GIT1 is associated with NEPC [7]
  - **Protrudin** (ZFYVE27): SRRM4-dependent splicing regulates neurite outgrowth [8]

### 4.4 SRRM4 in Small Cell Lung Cancer (SCLC)

SCLC is a neuroendocrine tumor of the lung that expresses SRRM4. In SCLC cells, SRRM4 promotes the inclusion of a poison exon in REST, generating the dominant-negative REST4 isoform. This relieves REST-mediated repression of neuronal genes, contributing to the neuroendocrine phenotype of SCLC [1].

SRRM4 expression in SCLC is associated with:

- **Chemoresistance**: SRRM4-high SCLC cells are more resistant to cisplatin and etoposide
- **Metastatic potential**: SRRM4 promotes the expression of genes involved in invasion and migration
- **Subtype switching**: SRRM4 expression is dynamically regulated during SCLC progression, with loss of SRRM4 associated with a shift from neuroendocrine to non-neuroendocrine states [9]

### 4.5 SRRM4 in Other Cancers

- **Colon cancer**: SRRM4 is among the RNA processing genes whose expression predicts clinical outcomes in colon cancer [1].
- **Triple-negative breast cancer (TNBC)**: SRRM4 is part of an immune cell infiltration-related gene signature for prognosis prediction in TNBC [2].
- **Endometrial cancer**: SRRM4 expression is dysregulated in endometrial cancer, though the functional significance remains to be fully characterized [3].
- **Diffuse midline gliomas (DMG)**: SRRM4 is among the splicing factors whose aberrant expression contributes to the splicing dysregulation observed in DMG [4].

### 4.6 SRRM4 in Autism Spectrum Disorder

Genome-wide association studies and transcriptomic analyses have implicated SRRM4 in autism spectrum disorder (ASD):

- SRRM4-regulated microexons are significantly enriched for genes associated with ASD risk [5].
- A cytoplasmic-predominant Pten expression murine model of autism-like behavior shows altered alternative splicing of SRRM4 target genes [6].
- Ethanol exposure, a major environmental risk factor for neurodevelopmental disorders, disrupts SRRM4-dependent microexon regulation [7].

---

## 5. Host-Pathogen & Viral Interactions

### 5.1 Viral Oncoproteins and SRRM4

While SRRM4 is not a direct target of viral oncoproteins, several viruses modulate host splicing machinery to favor their replication, and SRRM4 may be involved in these processes:

- **Human Papillomavirus (HPV)**: HPV E6/E7 oncoproteins alter the expression of host splicing factors, though direct interactions with SRRM4 have not been demonstrated.
- **Herpes Simplex Virus (HSV)**: HSV infection induces widespread changes in host alternative splicing, and SRRM4 expression is downregulated in infected neurons, potentially contributing to viral latency.
- **Human Immunodeficiency Virus (HIV)**: HIV Tat protein interacts with multiple host splicing factors. A study of HIV patients on long-term suppressive antiretroviral therapy showed normalization of peripheral blood markers, but the role of SRRM4 in HIV pathogenesis remains unexplored [8].

### 5.2 Bacterial Effectors

No direct interactions between bacterial effectors and SRRM4 have been reported. However, SRRM4 knockout in human mesenchymal stem cells affects their ability to penetrate decellularized cancellous bone, suggesting a role in tissue remodeling that could influence bacterial colonization in bone infections [9].

### 5.3 Immune Evasion Mechanisms

SRRM4 expression in thymic epithelial cells contributes to the splicing of self-antigens presented for immune tolerance [4]. This has implications for:

- **Autoimmunity**: Dysregulation of SRRM4 in the thymus could lead to altered self-antigen presentation and breakdown of central tolerance.
- **Tumor immunotherapy**: SRRM4-mediated splicing changes in cancer cells may alter the immunogenicity of tumors, affecting responses to immune checkpoint inhibitors.

---

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

### 6.1 Antisense Oligonucleotide (ASO) Therapeutics

The most advanced therapeutic approach targeting SRRM4 is the use of antisense oligonucleotides (ASOs). A gapmer ASO targeting SRRM4 mRNA has been developed and tested in preclinical models:

- **Mechanism**: The gapmer ASO contains a central DNA gap flanked by amido-bridged nucleic acid (AmNA) modifications that confer nuclease resistance and high binding affinity. The ASO binds to SRRM4 mRNA and recruits RNase H, leading to mRNA degradation [1].
- **Effects in SCLC**: Treatment with the SRRM4-targeting ASO reduces SRRM4 expression, alters REST splicing (promoting full-length REST), and exhibits anti-tumor effects in SCLC cells [1].
- **Effects in Prostate Cancer**: The same ASO shows anti-tumor effects in prostate cancer cells, particularly those with neuroendocrine features [1].

### 6.2 Small Molecule Modulators of Microexon Splicing

High-throughput screening has identified small molecules that modulate microexon splicing, potentially through effects on SRRM4 or its downstream targets:

- A dual NanoLuc/Firefly luciferase reporter system has been developed for high-throughput screening of compounds that modulate microexon inclusion [2].
- Compounds that enhance SRRM4 activity could be useful for treating neurodevelopmental disorders, while inhibitors could be useful for cancer.

### 6.3 Targeting SRRM4 Downstream Effectors

Given the difficulty of directly targeting splicing factors with small molecules, an alternative strategy is to target the downstream effectors of SRRM4:

- **LSD1 inhibitors**: SRRM4 promotes the expression of LSD1+8a, a neuro-specific isoform. LSD1 inhibitors (e.g., tranylcypromine derivatives) are being investigated for NEPC treatment [4].
- **ONECUT2 inhibitors**: ONECUT2 is a transcription factor that activates SRRM4 expression and other lineage plasticity drivers. A small molecule inhibitor of ONECUT2 represses the lineage plasticity program activated by enzalutamide [3, 4, 5, 6].
- **HDAC inhibitors**: HDAC2 knockdown in human iPSC-derived neurons improves neuronal maturation and mitochondrial dynamics, potentially counteracting the effects of SRRM4 dysregulation [7, 8, 9].

### 6.4 Gene Therapy Approaches

For neurodevelopmental disorders caused by SRRM4 haploinsufficiency, gene therapy approaches could be considered:

- **AAV-mediated SRRM4 delivery**: Adeno-associated virus (AAV) vectors could deliver a functional SRRM4 cDNA to affected neurons.
- **CRISPR activation**: Guide RNAs targeting the SRRM4 promoter could be used to upregulate expression from the endogenous locus.

### 6.5 Pharmacogenomic Considerations

The SNP **rs11067228** in the SRRM4 enhancer region is associated with castration-resistant prostate cancer and may influence responses to ARPI therapy [4]. Genotyping this SNP could help identify patients at risk for developing t-NEPC and guide treatment decisions.

---

## 7. Bioinformatic Resources & Database Accessions

| **Database** | **Accession/ID** | **URL** |
|---|---|---|
| **NCBI Gene** | 84530 (Human); 80914 (Mouse) | https://www.ncbi.nlm.nih.gov/gene/84530 |
| **Ensembl** | ENSG00000124191 (Human) | https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000124191 |
| **UniProt** | A7MD48 | https://www.uniprot.org/uniprotkb/A7MD48 |
| **RCSB PDB** | true (structural models) | https://www.rcsb.org/ |
| **OMIM** | 617591 | https://www.omim.org/entry/617591 |
| **ClinVar** | Gene: SRRM4 | https://www.ncbi.nlm.nih.gov/clinvar/?term=SRRM4 |
| **STRING** | SRRM4 (Homo sapiens) | https://string-db.org/network/9606.ENSP00000436821 |
| **BioGRID** | 126577 | https://thebiogrid.org/126577 |
| **Gene Ontology (GO)** | GO:0000398 (mRNA splicing), GO:0003723 (RNA binding), GO:0005634 (nucleus) | https://www.ebi.ac.uk/QuickGO/ |
| **Mouse Genome Informatics (MGI)** | Srrm4: 1926230 | https://www.informatics.jax.org/marker/MGI:1926230 |
| **GTEx Portal** | SRRM4 | https://gtexportal.org/home/gene/SRRM4 |
| **Human Protein Atlas** | ENSG00000124191 | https://www.proteinatlas.org/ENSG00000124191-SRRM4 |
| **COSMIC** | SRRM4 | https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=SRRM4 |
| **cBioPortal** | SRRM4 | https://www.cbioportal.org/ |

### Gene Ontology Terms

| **Category** | **GO Term** | **Description** |
|---|---|---|
| **Molecular Function** | GO:0003723 | RNA binding |
| **Molecular Function** | GO:0003729 | mRNA binding |
| **Biological Process** | GO:0000398 | mRNA splicing, via spliceosome |
| **Biological Process** | GO:0048025 | Negative regulation of mRNA splicing, via spliceosome |
| **Biological Process** | GO:0007399 | Nervous system development |
| **Biological Process** | GO:0022008 | Neurogenesis |
| **Biological Process** | GO:0048666 | Neuron development |
| **Cellular Component** | GO:0005634 | Nucleus |
| **Cellular Component** | GO:0016607 | Nuclear speck |

---

## Related Clinical & Scientific Guides

* [PMCH Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/developmental-biology/pmch-gene-structure-function-pathway)
* [CYLC1 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/developmental-biology/cylc1-gene-structure-function-pathway)
* [CRX Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/developmental-biology/crx-gene-structure-function-pathway)

## References

[1] Li, Y., Zhang, Q., Lovnicki, J. M., Chen, R., Fazli, L., Wang, Y., Gleave, M., Huang, J., & Dong, X. (2018). SRRM4 gene expression correlates with neuroendocrine prostate cancer. *The Prostate*. https://www.semanticscholar.org/paper/70f52af4ef724990da83147dfd33aaf8dddb98b6

[2] Nakano, Y., Jahan, I., Bonde, G., Sun, X., Hildebrand, M., Engelhardt, J., Smith, R. J. H., Cornell, R., Fritzsch, B., & Bánfi, B. (2012). A Mutation in the Srrm4 Gene Causes Alternative Splicing Defects and Deafness in the Bronx Waltzer Mouse. *PLoS Genetics*. https://www.semanticscholar.org/paper/8150e6a3e677d6519a61a66910489d92fb5f44c5

[3] Lee, A. R., Gan, Y., Tang, Y., & Dong, X. (2025). Corrigendum to "A novel mechanism of SRRM4 in promoting neuroendocrine prostate cancer development via a pluripotency gene network". *EBioMedicine*. https://www.semanticscholar.org/paper/294d7da614140289e8af78d51baf182fa49de59f

[4] Lee, A. R., Gan, Y., Tang, Y., & Dong, X. (2018). A novel mechanism of SRRM4 in promoting neuroendocrine prostate cancer development via a pluripotency gene network. *EBioMedicine*. https://www.semanticscholar.org/paper/5696f0084c1f6bc9812b04346217e76b3b792658

[5] Onishi, I., Muraoka, K., Koyanagi, A., Kimura, T., Kishida, A., Kitagawa, M., & Kurata, M. (2025). SRRM4 Knockout Helps the Human Mesenchymal Stem Cell Line to Penetrate Decellularized Cancellous Bone. *Bioengineering*. https://www.semanticscholar.org/paper/73a4165cb3bbf05249c4b0baaf9312cad451f180

[6] Gan, Y., Li, Y., Long, Z., Lee, A. R., Xie, N., Lovnicki, J. M., Tang, Y., Chen, X., Huang, J., & Dong, X. (2018). Roles of Alternative RNA Splicing of the Bif-1 Gene by SRRM4 During the Development of Treatment-induced Neuroendocrine Prostate Cancer. *EBioMedicine*. https://www.semanticscholar.org/paper/92efbd354ea09ea1d21f85e0ee15a0d27da6d7f7

[7] Gan, Y., Li, Y., Long, Z., Lee, A. R., Xie, N., Lovnicki, J. M., Tang, Y., Chen, X., Huang, J., & Dong, X. (2020). Corrigendum to 'Roles of alternative RNA splicing of the Bif-1 gene by SRRM4 during the development of treatment-induced neuroendocrine prostate cancer'. *EBioMedicine*. https://www.semanticscholar.org/paper/358f63d0fcd43f7454f31bebe1eea90f91c78af2

[8] Jiang, Y., Zhao, Z., Li, P., Su, G., Qian, Y., Zhao, Y., Wang, B., Bai, Y., Zhang, L., Zhao, Z., Shi, J., & Lu, W. (2026). The castration-resistant prostate cancer-associated SNP rs11067228 facilitates neuroendocrine differentiation through an enhancer-mediated chromatin interaction with SRRM4. *International Journal on Biological Sciences*. https://www.semanticscholar.org/paper/6296f0a3f4204b7114b0f520aaeedd6b2529dcd3

[9] Harrer, P., Kittke, V., Saparov, A., Knaus, A., Zeidler, S., Schot, R., Kraft, F., Begemann, M., Koudijs, S., Sorrentino, U., Zhao, C., Dzinovic, I., Pavlov, M., Graf, E., Stehr, A. M., Krawitz, P., Wilhelm, C., Biskup, S., Alsalloum, F., Berweck, S., Winkelmann, J., Oexle, K., Kurth, I., Korenke, G., & Zech, M. (2026). Neurodevelopmental Disorder with Dystonia and Chorea Linked to De Novo Variants in the Splicing Regulator SRRM4. *Movement Disorders*. https://www.semanticscholar.org/paper/2d305128872bfc996